Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials (Q36221963)

12 August 2017

0 references

1 reference

title

Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials (English)

1 reference

12 August 2017

1 reference

2

Bryan T Hennessy

1 reference

12 August 2017

Emer O Hanrahan

1

1 reference

PubMed ID

16086636

12 August 2017

Vicente Valero

series ordinal

3

1 reference

PubMed ID

16086636

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

1 reference

12 August 2017

6

1 reference

12 August 2017

9

1 reference

12 August 2017

1477-1491

1 reference

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Neoadjuvant endocrine therapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Sentinel lymph node biopsy after neoadjuvant systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1477

10.1517/14656566.6.9.1477

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16086636